References
- Josephson F, Albert J, Flamholc L, Gisslen M, Karlstrom O, Moberg L, . Treatment of HIV infection: Swedish recommendations 2009. Scand J Infect Dis 2009;4:1–20.
- Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, . Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006;43: 27–34.
- Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, . Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853–60.
- Larsen MV, Omland LH, Gerstoft J, Roge BT, Larsen CS, Pedersen G, . Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: a nationwide population-based cohort study. Scand J Infect Dis 2010;42:917–23.
- Gerstoft JM, Lundgren JD, Nielsen HI, Pedersen C, Obel Niels, Laursen A. Guidelines for HIV treatment. Danish Society of Infectious Diseases; 2010. Available at: http://dsinfm.dk/file.php?name = /files/pdf/Retningslinier%20for%20HIV%20behandling%20(DSI%202010).pdf (Accessed 19 September 2011).
- Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, . Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009;373:1352–63.
- Guidance for Industry. Antiretroviral drugs using plasma HIV RNA measurements—clinical considerations for accelerated and traditional approval. US Department of Health and Human Services/Food and Drug Administration/Center for Drug Evaluation and Research (CDER); October 2002. Available at: http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/ucm070968.pdf (Accessed 19 September 2011).
- Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, van Lunzen J, . Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med 2000;160:1123–32.
- Deeks SG, Gange SJ, Kitahata MM, Saag MS, Justice AC, Hogg RS, . Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis 2009;49:1582–90.(Accessed 19 September 2011)
- Kalichman SC, Amaral CM, Cherry C, Flanagan J, Pope H, Eaton L, . Monitoring medication adherence by unannounced pill counts conducted by telephone: reliability and criterion-related validity. HIV Clin Trials 2008; 9:298–308.
- Jensen-Fangel S, Pedersen L, Pedersen C, Larsen CS, Tauris P, Moller A, . The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients. Clin Infect Dis 2002; 35:1541–8.
- Hartzell JD, Spooner K, Howard R, Wegner S, Wortmann G. Race and mental health diagnosis are risk factors for highly active antiretroviral therapy failure in a military cohort despite equal access to care. J Acquir Immune Defic Syndr 2007;44: 411–6.
- Weintrob AC, Grandits GA, Agan BK, Ganesan A, Landrum ML, Crum-Cianflone NF, . Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care. J Acquir Immune Defic Syndr 2009; 52:574–80.